INTRODUCTION: Advances in the rate of success of human islet isolation are due in part to the availability of new purified enzyme blends. In this study we evaluated a new enzyme preparation composed of a highly purified collagenase that can be reproducibly blended with predetermined amounts of separately packaged neutral protease. METHODS: Nine human islet isolations were performed with collagenase NB1 supplemented with neutral protease (Serva Electrophoresis GMbH, group I). Yields, purity, morphology, in vitro function and islet cell apoptosis were assessed. The results were compared to those of nine human islet isolations performed with Liberase (Roche, group II) and matched for donor age, BMI, and circumstances of death. RESULTS: Islet yields were similar in both groups. However, islet equivalents (IE) per gram of pancreas and IE number to islet number were higher in group I (P <.05). Stimulation indices after insulin response to glucose (static incubation) were similar in both groups. Islet cell apoptosis rate was statistically significantly lower in group I. Islet morphology was significantly improved in group I with a higher proportion of intact islets. CONCLUSION: This new enzyme preparation (collagenase NB1 with neutral protease adjunct) was as effective as Liberase in terms of islet yields and function. Islet morphology was improved and rate of islet cell apoptosis was lower with this new collagenase. The absence of lot-to-lot variability in terms of neutral protease to collagenase ratio makes collagenase NB1 a promising enzyme for human islet isolation.
INTRODUCTION: Advances in the rate of success of human islet isolation are due in part to the availability of new purified enzyme blends. In this study we evaluated a new enzyme preparation composed of a highly purified collagenase that can be reproducibly blended with predetermined amounts of separately packaged neutral protease. METHODS: Nine human islet isolations were performed with collagenase NB1 supplemented with neutral protease (Serva Electrophoresis GMbH, group I). Yields, purity, morphology, in vitro function and islet cell apoptosis were assessed. The results were compared to those of nine human islet isolations performed with Liberase (Roche, group II) and matched for donor age, BMI, and circumstances of death. RESULTS: Islet yields were similar in both groups. However, islet equivalents (IE) per gram of pancreas and IE number to islet number were higher in group I (P <.05). Stimulation indices after insulin response to glucose (static incubation) were similar in both groups. Islet cell apoptosis rate was statistically significantly lower in group I. Islet morphology was significantly improved in group I with a higher proportion of intact islets. CONCLUSION: This new enzyme preparation (collagenase NB1 with neutral protease adjunct) was as effective as Liberase in terms of islet yields and function. Islet morphology was improved and rate of islet cell apoptosis was lower with this new collagenase. The absence of lot-to-lot variability in terms of neutral protease to collagenase ratio makes collagenase NB1 a promising enzyme for human islet isolation.
Authors: A N Balamurugan; Gopalakrishnan Loganathan; Melena D Bellin; Joshua J Wilhelm; James Harmon; Takayuki Anazawa; Sajjad M Soltani; David M Radosevich; Takeshi Yuasa; Mukesh Tiwari; Klearchos K Papas; Robert McCarthy; David E R Sutherland; Bernhard J Hering Journal: Transplantation Date: 2012-04-15 Impact factor: 4.939
Authors: R Misawa; C Ricordi; A Miki; S Barker; R D Molano; A Khan; S Miyagawa; L Inverardi; R Alejandro; A Pileggi; H Ichii Journal: Cell Transplant Date: 2011-09-16 Impact factor: 4.064
Authors: A M Posselt; M D Bellin; M Tavakol; G L Szot; L A Frassetto; U Masharani; R K Kerlan; L Fong; F G Vincenti; B J Hering; J A Bluestone; P G Stock Journal: Am J Transplant Date: 2010-08 Impact factor: 8.086
Authors: Gregory L Szot; Michael R Lee; Mohammad M Tavakol; Jiena Lang; Florinna Dekovic; Robert K Kerlan; Peter G Stock; Andrew M Posselt Journal: Transplantation Date: 2009-09-27 Impact factor: 4.939
Authors: A N Balamurugan; B Naziruddin; A Lockridge; M Tiwari; G Loganathan; M Takita; S Matsumoto; K Papas; M Trieger; H Rainis; T Kin; T W Kay; S Wease; S Messinger; C Ricordi; R Alejandro; J Markmann; J Kerr-Conti; M R Rickels; C Liu; X Zhang; P Witkowski; A Posselt; P Maffi; A Secchi; T Berney; P J O'Connell; B J Hering; F B Barton Journal: Am J Transplant Date: 2014-10-02 Impact factor: 8.086
Authors: Nicole Corrales; Soomin Park; Hien Lau; Ivana Xu; Colleen Luong; Samuel Rodriguez; Johanna Mönch; Michael Alexander; Jonathan Rt Lakey Journal: Cell Transplant Date: 2020 Jan-Dec Impact factor: 4.064
Authors: Michael R Rickels; Chengyang Liu; Richard D Shlansky-Goldberg; Scott A Soleimanpour; Kumar Vivek; Malek Kamoun; Zaw Min; Eileen Markmann; Maral Palangian; Cornelia Dalton-Bakes; Carissa Fuller; Allen J Chiou; Clyde F Barker; Eline T Luning Prak; Ali Naji Journal: Diabetes Date: 2013-04-29 Impact factor: 9.461
Authors: Magnus Ståhle; Aksel Foss; Bengt Gustafsson; Marko Lempinen; Torbjörn Lundgren; Ehab Rafael; Gunnar Tufveson; Olle Korsgren; Andrew Friberg Journal: Transplant Direct Date: 2015-06-24